Abstract:Kinase inhibition is an increasingly popular strategy for pharmacotherapy of human diseases. Although many of these agents have been described as "targeted therapy", they will typically inhibit multiple kinases with varying potency. Pre-clinical model testing has not predicted the numerous significant toxicities identified during clinical development. The purpose of this study was to develop a bioinformatics-based method to predict specific adverse events (AEs) in humans associated with the inhibition of particular kinase targets (KTs).The AE frequencies of protein kinase inhibitors (PKIs) were curated from three sources (PubMed, Thompson Physician Desk Reference and PharmGKB), and affinities of 38 PKIs for 317 kinases, representing >50% of the predicted human kinome, were collected from published in vitro assay results. A novel quantitative computational method was developed to predict associations between KTs and AEs that included a whole panel of 71 AEs and 20 PKIs targeting 266 distinct kinases with K(d)<10microM. The method calculated an unbiased, kinome-wide association score via linear algebra on (i) the normalized frequencies of AEs associated with 20 PKIs and (ii) the negative log-transformed dissociation constant of kinases targeted by these PKIs. Finally, a reference standard was calculated by applying Fisher's exact test to the co-occurrence of indexed Pubmed terms (p0.05, and manually verified) for AE and associated kinase targets (AE-KT) pairs from standard literature search techniques. We also evaluated the enrichment of predictions between the quantitative method and the literature search by Fisher's exact testing.We identified significant associations among already empirically well established pairs of AEs (e.g. diarrhea and rash) and KTs (e.g. EGFR). The following less well recognized AE-KT pairs had similar association scores: diarrhea-(DDR1;ERBB4), rash-ERBB4, and fatigue-(CSF1R;KIT). With no filtering, the association score identified 41 prioritized associations involving 7 AEs and 19 KTs. Among them, eight associations were reported in the literature review. There were only 78 out of a total of 4522 AE-KT pairs meeting the evaluation threshold, indicating a strong association between the predicted and the text mined AE-KT pairs (p=3x10(-7)). As many of these drugs remain in development, a larger volume of more detailed data on AE-PKI associations is accessible only through non-public databases. These prediction models will be refined with these data and validated through dedicated prospective human studies. CONCLUSION AND FUTURE DIRECTIONS: Our in silico method can predict associations between kinase targets and AE frequencies in human patients. Refining this method should lead to improved clinical development of protein kinase inhibitors, a large new class of therapeutics. http://www.lussierlab.org/publication/PAS/.

Artificial intelligence methods in kinase target profiling: advances and challenges

Large-scale comparison of machine learning methods for profiling prediction of kinase inhibitors

Kinase Drug Discovery: Impact of Open Science and Artificial Intelligence

Web Support for the More Efficient Discovery of Kinase Inhibitors

Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks

Abstract 4910: AI predicts drug response from the genomic features of cells and the kinase activity changes induced by compounds

Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments

High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome

Large-scale Prediction of Human Kinase-Inhibitor Interactions Using Protein Sequences and Molecular Topological Structures.

Unlocking the Potential of Kinase Targets in Cancer: Insights from CancerOmicsNet, an AI-Driven Approach to Drug Response Prediction in Cancer

Strategy toward Kinase-Selective Drug Discovery

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

[Progress in the Design of Selective ATP-competitive Kinase Inhibitors].

A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery

MinKLIFSAI: a simple machine learning approach toward selective kinase inhibitor

Comprehensive evaluation of phosphoproteomic-based kinase activity inference

Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors